Search results
Psoriasis: Features That May Affect Biologic Rx Outcomes
Medscape· 5 days agoSeveral clinical characteristics were negatively associated with responses to biologics in a...
FDA Approves Skyrizi for Ulcerative Colitis
Medscape· 4 days agoThe approval is the fourth indication for the anti–interleukin 23 monoclonal antibody after approval for Crohn's disease, psoriatic arthritis, and plaque...
Did Teva Pharmaceutical Industries Limited (TEVA)’s “Pivot to Growth” Strategy Help It Get a...
Insider Monkey via Yahoo Finance· 7 hours agoWe recently compiled a list of the 10 Best Robinhood Stocks Under $20. In this article, we are going...
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
Zacks via Yahoo Finance· 1 day agoJ&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's...
Teachers Retirement System of The State of Kentucky Sells 2,047 Shares of Amgen Inc. (NASDAQ:AMGN)
ETF DAILY NEWS· 6 days agoTeachers Retirement System of The State of Kentucky trimmed its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 1.5% during the 4th quarter, according to the company in its most recent ...
AbbVie Inc. (NYSE:ABBV) Shares Bought by Pathway Financial Advisors LLC
ETF DAILY NEWS· 6 hours agoPathway Financial Advisors LLC raised its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 3.7% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 3,110 ...
American National Bank Acquires 1,816 Shares of AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 5 hours agoAmerican National Bank grew its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 3.1% during the first quarter, according to its most recent filing with the Securities and Exchange ...
AbbVie Inc. (NYSE:ABBV) Stock Holdings Boosted by Inscription Capital LLC
ETF DAILY NEWS· 6 hours agoInscription Capital LLC raised its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 20.9% in the first quarter, according to the company in its most recent 13F filing with the ...
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the ...
Morningstar· 2 days agoFood and Drug Administration (FDA) seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active Crohn's disease. The submission ...
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 3 days agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In April, the North Chicago ...